However, further studies are needed to clarify the role of the aspartate/L-arginine axis in obesity and body fat distribution, and in particular, to determine whether oral supplementation with either L-arginine or aspartate may reduce fat deposition in the Cyp17a1 KO mouse model. The gene discussed is CYP17A1; the disease is obesity disorder.